MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback